Interplay between epigenetic alterations and piRNA expression in cancer development
- 1Institute of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, Hunan, China
Abstract
PIWI-interacting RNAs (piRNAs) are small non-coding RNAs generated from longer precursor transcripts through primary processing and, in selected biological contexts, a secondary ping-pong amplification cycle. They associate with PIWI proteins to target and silence transposable elements (TEs), and dysregulation of the PIWI-piRNA pathway has been reported in multiple human cancers. In physiological germline models, epigenetic modifications – including DNA methylation, histone modifications, RNA modifications, and chromatin remodeling – coordinately regulate the activity of piRNA clusters to ensure proper piRNA biogenesis. However, in tumor cells, how epigenetic modifications influence piRNA transcription and processing remains poorly characterized, with most studies focusing on how dysregulated piRNAs drive tumorigenesis via epigenetic or epitranscriptomic mechanisms. This review also discusses species-specific differences, limitations in somatic piRNA annotation, and the evidence needed to distinguish association from mechanism. DNMT/HDAC inhibitors, dietary bioactive compounds, and deactivated Cas9 (dCas9)-based epigenome editing may provide useful experimental or therapeutic approaches, but piRNA-directed epigenetic therapy remains preclinical.
Related
- ESM1-mediated DNMT3A suppresses cervical cancer metastasis through epigenetic regulation of ID3 expression
- Environmental chemical mixtures reprogram mammary epithelial development to epigenetic states associated with breast cancer.
- Dynamic regulation of cystathionine gamma-lyase expression during normoxia, ischemia, and reperfusion in liver: interplay of transcription factors, microRNAs, and histone modifications
- Early epigenetic alterations in cardiac tissue following perinatal sertraline exposure in mice
- Efficient base editing and development in human embryos without chromosomal alterations
BibTeX
@article{peng2026interplay,
title = {{Interplay between epigenetic alterations and piRNA expression in cancer development}},
author = {Siyun Peng and Hangyu Wang and Ermao Li},
journal = {Epigenetics},
year = {2026},
month = nov,
doi = {10.1080/15592294.2026.2758456},
url = {https://doi.org/10.1080/15592294.2026.2758456},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Interplay between epigenetic alterations and piRNA expression in cancer development
AU - Siyun Peng
AU - Hangyu Wang
AU - Ermao Li
PY - 2026
DA - 2026/11/09
JO - Epigenetics
DO - 10.1080/15592294.2026.2758456
UR - https://doi.org/10.1080/15592294.2026.2758456
AB - PIWI-interacting RNAs (piRNAs) are small non-coding RNAs generated from longer precursor transcripts through primary processing and, in selected biological contexts, a secondary ping-pong amplification cycle. They associate with PIWI proteins to target and silence transposable elements (TEs), and dysregulation of the PIWI-piRNA pathway has been reported in multiple human cancers. In physiological germline models, epigenetic modifications – including DNA methylation, histone modifications, RNA modifications, and chromatin remodeling – coordinately regulate the activity of piRNA clusters to ensure proper piRNA biogenesis. However, in tumor cells, how epigenetic modifications influence piRNA transcription and processing remains poorly characterized, with most studies focusing on how dysregulated piRNAs drive tumorigenesis via epigenetic or epitranscriptomic mechanisms. This review also discusses species-specific differences, limitations in somatic piRNA annotation, and the evidence needed to distinguish association from mechanism. DNMT/HDAC inhibitors, dietary bioactive compounds, and deactivated Cas9 (dCas9)-based epigenome editing may provide useful experimental or therapeutic approaches, but piRNA-directed epigenetic therapy remains preclinical.
SN - 1559-2294
SN - 1559-2308
ER -